Adage Capital Partners Gp, L.L.C. Terns Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,280,000 shares of TERN stock, worth $10.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,280,000Holding current value
$10.4 Million% of portfolio
0.01%Shares
6 transactions
Others Institutions Holding TERN
# of Institutions
135Shares Held
84.3MCall Options Held
173KPut Options Held
89.5K-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$66.1 Million2.36% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$61.2 Million1.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.5MShares$60.6 Million0.99% of portfolio
-
Morgan Stanley New York, NY7.25MShares$58.7 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$55.8 Million5.45% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $304M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...